XML 100 R80.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information and Geographic Data - Operating Segment Selected Financial Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue:      
Revenue $ 677,564 $ 423,239 $ 270,259
Operating expenses:      
Cost of goods sold 77,673 60,910 33,407
Collaboration expenses 229,545 128,311 56,524
Direct research and development expenses by program:      
Research and development 96,853 111,623 76,097
Selling, general and administrative 196,272 168,011 129,427
Total operating expenses 600,343 468,855 295,455
Other income, net 11,647 9,464 8,544
Income (loss) before income taxes 88,868 (36,152) (16,652)
Benefit (provision) for income taxes (29,863) (7,041) 30,736
Net income (loss) 59,005 (43,193) 14,084
Other significant non-cash items:      
Share-based compensation expense 37,003 30,693 27,149
Non-cash lease expense 3,666 3,136 3,054
Deferred income taxes 13,002 8,132 (33,788)
ARCALYST      
Direct research and development expenses by program:      
Research and development 1,040 1,080 2,628
KPL-387      
Direct research and development expenses by program:      
Research and development 47,265 11,221 2,537
KPL-1161      
Direct research and development expenses by program:      
Research and development 4,198 581  
Abiprubart      
Direct research and development expenses by program:      
Research and development 6,122 59,459 28,388
Vixarelimab      
Direct research and development expenses by program:      
Research and development 44 1,530 7,717
Unallocated research and development expenses      
Direct research and development expenses by program:      
Research and development 38,184 37,752 34,827
Product revenue, net      
Revenue:      
Revenue 677,564 417,029 233,176
License and collaboration revenue      
Revenue:      
Revenue   6,210 37,083
Pharmaceutical      
Revenue:      
Revenue $ 677,564 $ 423,239 $ 270,259